# Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel

> **NCT04237090** · PHASE3 · COMPLETED · sponsor: **Ciusss de L'Est de l'Île de Montréal** · enrollment: 27 (actual)

## Conditions studied

- Breast Cancer
- Lung Cancer
- Ovarian Cancer
- Oesophageal Cancer
- Head Cancer Neck
- Cervical Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** Diphenhydramine
- **DRUG:** Cetirizine
- **DRUG:** Lactose pill
- **DRUG:** Sodium chloride 0.9%

## Key facts

- **NCT ID:** NCT04237090
- **Lead sponsor:** Ciusss de L'Est de l'Île de Montréal
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-14
- **Primary completion:** 2020-08-28
- **Final completion:** 2020-09-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04237090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04237090, "Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04237090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*